Lilly’s Orforglipron Demonstrates Superiority in Phase 3 Diabetes Trials

Eli Lilly’s “Ozempic-in-a-pill” candidate just cleared its most significant clinical hurdle to date. The pharmaceutical giant announced that its experimental once-daily pill, orforglipron, met all primary and secondary endpoints in two pivotal Phase 3 trials: ACHIEVE-2 and ACHIEVE-5.

Data indicate that this oral treatment provides superior glycemic control compared to both a standard SGLT-2 inhibitor and a placebo. If approved, this small-molecule agonist could fundamentally disrupt the diabetes landscape by offering the high-potency results of injectables in a convenient daily tablet.

The findings, released in October 2025, show that orforglipron achieved significant reductions in A1C levels — the standard measure of average blood sugar — and body weight over a 40-week period. Unlike current oral GLP-1 options, orforglipron is a non-peptide, small-molecule drug.

This chemical structure is clinically significant; while “peptide” drugs are proteins usually digested by stomach enzymes, this non-peptide version is sturdy enough to be absorbed as a pill without restrictive food or water requirements. Orforglipron belongs to the GLP-1 (glucagon-like peptide-1) receptor agonist class, mimicking a gut hormone that triggers insulin release and slows digestion.